丽珠集团(000513) - 2024年12月4日投资者关系活动记录表

Financial Performance - In the first three quarters of 2024, the company's overall performance remained stable, with a noticeable reduction in sales and R&D expense ratios, indicating improved operational quality [2] - Revenue from hormone products reached CNY 2.308 billion, with a growth rate of 5.46% [6] - Revenue from traditional Chinese medicine (TCM) formulations was CNY 1.041 billion, reflecting a year-on-year decline of 16.49% due to normalization of sales after last year's pandemic-related spikes [6][7] R&D and Product Development - The company has made strategic adjustments in R&D, focusing on innovative drug development and optimizing the R&D organizational structure [3][4] - The company has introduced several innovative drugs in the fields of neurology, anti-infection, and reproductive health, enhancing its product pipeline [4][5] - The company is advancing its micro-sphere platform, with several products undergoing clinical trials and approvals, including long-acting formulations [5][6] Share Buyback and Dividend Policy - Since 2020, the company has launched four share buyback plans, with the latest plan involving a buyback amount of CNY 600 million to CNY 1 billion at a price not exceeding CNY 45 per share [3] - The company is in a strong position to distribute dividends, with no major capital expenditure plans on the horizon, and is considering shareholder returns in future dividend strategies [3] Market Strategy and Sales - The company is exploring direct sales models and has initiated pilot programs in several provinces, aiming to enhance its sales efficiency [5] - There is a focus on compliance marketing and optimizing sales expenses to maximize sales effectiveness while seeking international market opportunities [5] Regulatory and Competitive Landscape - The company is actively pursuing international collaborations and licensing agreements to expand its product reach and enhance global competitiveness [4][5] - The company’s innovative IL-17A/F monoclonal antibody is in phase III clinical trials, positioning it uniquely in the domestic market against existing competitors [7][8]